The identification of oncogenic driver mutations has transformed the therapeutic landscape for NSCLC, with Epidermal Growth Factor Receptor (EGFR) mutations observed in approximately 15–50% of advanced cases [2]. Here, EGFR is linked to non-small cell lung carcinoma.